QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 2, 页码: 875-892 作者:  Liang, Xiaofei;  Wang, Beilei;  Chen, Cheng;  Wang, Aoli;  Hu, Chen 收藏  |  浏览/下载：20/0  |  提交时间：2020/05/21 Discovery of N-phenyl)-2-phenyl)acetamide as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Mutant Selective Inhibitor for Acute Myeloid Leukemia 期刊论文 Journal of Medicinal Chemistry, 2019, 卷号: Vol.62 No.2, 页码: 875-892 作者:  Tingting Lu;  Jian Ge;  Tao Ren;  Wenchao Wang;  Junjie Wang 收藏  |  浏览/下载：36/0  |  提交时间：2019/04/24 Discovery of N-phenyl)-2-phenyl)acetamide as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Mutant Selective Inhibitor for Acute Myeloid Leukemia 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: Vol.62 No.2, 页码: 875-892 作者:  Wang, Beilei;  Li, Feng;  Liu, Qingwang;  Hu, Zhenquan;  Liang, Xiaofei 收藏  |  浏览/下载：4/0  |  提交时间：2019/04/24 Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation 期刊论文 2019, 卷号: 25, 期号: 8, 页码: 1674-1681 作者:  Xuan Li;  Wang Yu;  Chen Jia;  Jiang Erlie;  Gao Li 收藏  |  浏览/下载：17/0  |  提交时间：2020/01/03 Acute myeloid leukemia  Allogeneic hematopoietic stem cell transplantation  FMS-like tyrosine kinase 3 internal tandem duplication  Relapse  Sorafenib   Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT 期刊论文 2019 作者:  Xuan Li;  Wang Yu;  Chen Jia;  Jiang Erlie;  Gao Li 收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03 FMS-like tyrosine kinase 3 internal tandem duplication  acute myeloid leukemia  allogeneic hematopoietic stem cell transplantation  relapse  sorafenib